ezm0414
ezm0414: sourced relationships with 1 company · 1 clinical trial tracked.
ezm0414 evidence translation
What we can confirm
1 tracked trial
What it means
What to watch
Prepared research question
How could ezm0414 → EPZM affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Epizyme, Inc. (EPZM) Multiple Myeloma, Refractory | Phase 1 |
Clinical Trial Registry Records (1)
A Phase 1/1b, Open-label Multi-center Two-part Study of SETD2 Inhibitor EZM0414 in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
Primary endpoint: Part 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
Frequently asked questions
Which companies have sourced relationships with ezm0414?
ezm0414 has dated SEC/FDA relationship records for Epizyme, Inc..
How many clinical trials involve ezm0414?
BioSniper tracks 1 clinical trial involving ezm0414.